Cargando…

Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells

Multiple myeloma (MM) is an incurable B cell neoplasia characterized by the accumulation of tumor plasma cells within the bone marrow (BM). As a consequence, bone osteolytic lesions develop in 80% of patients and remain even after complete disease remission. We and others had demonstrated that BM-de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espagnolle, Nicolas, Hebraud, Benjamin, Descamps, Jean-Gérard, Gadelorge, Mélanie, Joubert, Marie-Véronique, Ferreira, Laura Do Souto, Roussel, Murielle, Huynh, Anne, Sensébé, Luc, Casteilla, Louis, Attal, Michel, Avet-Loiseau, Hervé, Deschaseaux, Frederic, Bourin, Philippe, Corre, Jill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077052/ https://www.ncbi.nlm.nih.gov/pubmed/32215016 http://dx.doi.org/10.1155/2020/4173578

Ejemplares similares

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
por: Lemaitre, Léa, et al.
Publicado: (2022)

CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment
por: Espagnolle, Nicolas, et al.
Publicado: (2014)

Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma
por: Lemaitre, Léa, et al.
Publicado: (2020)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021)

Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials
por: Philippe, Bourin, et al.
Publicado: (2010)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review
por: Sensebé, Luc, et al.
Publicado: (2013)

Human adipose stromal-vascular fraction self-organizes to form vascularized adipose tissue in 3D cultures
por: Muller, Sandra, et al.
Publicado: (2019)

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020)

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2023)

Rationale for Determining the Functional Potency of Mesenchymal Stem Cells in Preventing Regulated Cell Death for Therapeutic Use
por: Naji, Abderrahim, et al.
Publicado: (2016)

CD54-Mediated Interaction with Pro-inflammatory Macrophages Increases the Immunosuppressive Function of Human Mesenchymal Stromal Cells
por: Espagnolle, Nicolas, et al.
Publicado: (2017)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components
por: Fekete, Natalie, et al.
Publicado: (2012)

Pericyte-Like Progenitors Show High Immaturity and Engraftment Potential as Compared with Mesenchymal Stem Cells
por: Bouacida, Amina, et al.
Publicado: (2012)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
por: Bradwell, A, et al.
Publicado: (2013)

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
por: Michallet, M, et al.
Publicado: (2018)

Expressed fusion gene landscape and its impact in multiple myeloma
por: Cleynen, A., et al.
Publicado: (2017)

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
por: Schavgoulidze, Anaïs, et al.
Publicado: (2023)

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma
por: Alberge, Jean-Baptiste, et al.
Publicado: (2020)

Bone regeneration: the stem/progenitor cells point of view
por: Deschaseaux, Frédéric, et al.
Publicado: (2010)

Deciphering the chronology of copy number alterations in Multiple Myeloma
por: Aktas Samur, Anil, et al.
Publicado: (2019)

Logic programming reveals alteration of key transcription factors in multiple myeloma
por: Miannay, Bertrand, et al.
Publicado: (2017)

Single-cell RNA sequencing of human non-hematopoietic bone marrow cells reveals a unique set of inter-species conserved biomarkers for native mesenchymal stromal cells
por: Fiévet, Loïc, et al.
Publicado: (2023)

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
por: Aktas Samur, Anil, et al.
Publicado: (2022)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple Myeloma
por: Cormier, Françoise, et al.
Publicado: (2013)

Native human adipose stromal cells: localization, morphology and phenotype
por: Maumus, M, et al.
Publicado: (2011)

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
por: Samur, Mehmet Kemal, et al.
Publicado: (2020)

Aggressive FLC Escape in a Patient with IgD Myeloma
por: Farges, Cédric, et al.
Publicado: (2015)

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
por: Kendrick, Felicity, et al.
Publicado: (2017)

Urokinase-type plasminogen activator receptor interaction with β1 integrin is required for platelet-derived growth factor-AB-induced human mesenchymal stem/stromal cell migration
por: Chabot, Valérie, et al.
Publicado: (2015)

The shaping and functional consequences of the dosage effect landscape in multiple myeloma
por: Samur, Mehmet K, et al.
Publicado: (2013)

Inferior In Vivo Osteogenesis and Superior Angiogeneis of Human Adipose Tissue: A Comparison with Bone Marrow‐Derived Stromal Stem Cells Cultured in Xeno‐Free Conditions
por: Brennan, Meadhbh A., et al.
Publicado: (2017)

CD200R/CD200 Inhibits Osteoclastogenesis: New Mechanism of Osteoclast Control by Mesenchymal Stem Cells in Human
por: Varin, Audrey, et al.
Publicado: (2013)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_onkljfdag3l1vpn8olpeu94epr